384 related articles for article (PubMed ID: 35095993)
21. N6-methyladenosine related gene expression signatures for predicting the overall survival and immune responses of patients with colorectal cancer.
Yu L; Wang L; Sun J; Zhou X; Hu Y; Hu L; He Y; Lin C; Chen J; Xu X; Dunlop MG; Theodoratou E; Ding K; Li X
Front Genet; 2023; 14():885930. PubMed ID: 36936424
[TBL] [Abstract][Full Text] [Related]
22. Analysis of m6A-related signatures associated with the tumor immune microenvironment and predict survival in acute myeloid leukemia.
Yuan S; Cong Z; Ji J; Zhu L; Jiang Q; Zhou Y; Shen Q; Damiani D; Xu X; Li B
Ann Transl Med; 2022 Aug; 10(16):902. PubMed ID: 36111007
[TBL] [Abstract][Full Text] [Related]
23. Construction and validation of an m6A RNA methylation regulator prognostic model for early-stage clear cell renal cell carcinoma.
Wang Z; Zhang M; Seery S; Zheng G; Wang W; Zhao Y; Wang X; Zhang Y
Oncol Lett; 2022 Aug; 24(2):250. PubMed ID: 35761938
[TBL] [Abstract][Full Text] [Related]
24. Effect of N6-methyladenosine (m6A) regulator-related immunogenes on the prognosis and immune microenvironment of breast cancer.
Yu Z; He Q; Xu G
Transl Cancer Res; 2022 Dec; 11(12):4303-4314. PubMed ID: 36644186
[TBL] [Abstract][Full Text] [Related]
25. Construction of an N6-methyladenosine lncRNA- and immune cell infiltration-related prognostic model in colorectal cancer.
Yu ZL; Zhu ZM
Protoplasma; 2022 Jul; 259(4):1029-1045. PubMed ID: 34734333
[TBL] [Abstract][Full Text] [Related]
26. Identification of an N6-methyladenosine (m6A)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas.
Cai Z; Zhang J; Liu Z; Su J; Xu J; Li Z; Meng H; Zhang H; Huang M; Zhao D; Duan C; He X
Ann Transl Med; 2021 Aug; 9(15):1241. PubMed ID: 34532378
[TBL] [Abstract][Full Text] [Related]
27. m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer.
Chen M; Nie ZY; Wen XH; Gao YH; Cao H; Zhang SF
Biosci Rep; 2019 Dec; 39(12):. PubMed ID: 31808521
[TBL] [Abstract][Full Text] [Related]
28. N6-Methyladenosine-Related lncRNAs as potential biomarkers for predicting prognoses and immune responses in patients with cervical cancer.
Zhang H; Kong W; Zhao X; Han C; Liu T; Li J; Song D
BMC Genom Data; 2022 Jan; 23(1):8. PubMed ID: 35042477
[TBL] [Abstract][Full Text] [Related]
29. Identification of Prognostic Markers of N6-Methylandenosine-Related Noncoding RNAs in Non-Small-Cell Lung Cancer.
Zhang Z; Li J; Lu K; Wu W; Huang Z; Zhang C; Guo W; Li J; Lin L
J Oncol; 2022; 2022():3657349. PubMed ID: 35401751
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of N6-Methyladenosine-Related lncRNAs in Early-Stage Colorectal Cancer: Association With Immune Cell Infiltration and Chemotherapeutic Drug Sensitivity.
Xiong Z; Li X; Yin S; Xie M; Mao C; Zhang F; Chen H; Jin L; Lian L
Front Mol Biosci; 2021; 8():724889. PubMed ID: 34712696
[No Abstract] [Full Text] [Related]
31. m6A regulator-mediated methylation modification patterns and tumor microenvironment immune infiltration with prognostic analysis in esophageal cancer.
Sheng G; Wang T; Gao Y; Wu H; Wu J
Sci Rep; 2023 Nov; 13(1):19670. PubMed ID: 37952076
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
Front Immunol; 2021; 12():769425. PubMed ID: 34804059
[TBL] [Abstract][Full Text] [Related]
33. An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment.
Du Y; Ma Y; Zhu Q; Liu T; Jiao Y; Yuan P; Wang X
Front Pharmacol; 2021; 12():707930. PubMed ID: 34248650
[No Abstract] [Full Text] [Related]
34. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
Liu X; Ma C; Liu H; Sun Z; Luo J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
[TBL] [Abstract][Full Text] [Related]
35. Identification and validation of an m6A-related gene signature to predict prognosis and evaluate immune features of breast cancer.
Li W; Wang X; Li C; Chen T; Zhou X; Li Z; Yang Q
Hum Cell; 2023 Jan; 36(1):393-408. PubMed ID: 36403174
[TBL] [Abstract][Full Text] [Related]
36. Construction of a Novel Signature and Prediction of the Immune Landscape in Soft Tissue Sarcomas Based on N6-Methylandenosine-Related LncRNAs.
Zhang L; Tang X; Wan J; Zhang X; Zheng T; Lin Z; Liu T
Front Mol Biosci; 2021; 8():715764. PubMed ID: 34733885
[No Abstract] [Full Text] [Related]
37. Thyroid cancer risk prediction model using m6A RNA methylation regulators: integrated bioinformatics analysis and histological validation.
Zhou W; Lin J; Liu J; Zhang R; Fan A; Xie Q; Hong L; Fan D
Aging (Albany NY); 2023 Feb; 15(3):846-865. PubMed ID: 36791151
[TBL] [Abstract][Full Text] [Related]
38. Construction and validation of a m6A RNA methylation and ferroptosis-related prognostic model for pancreatic cancer by integrated bioinformatics analysis.
Wu T; Qian TY; Lin RJ; Jin DD; Xu XB; Huang MX; Ji J; Jiang F; Pan LL; Luo L; Ji YF; Chen QL; Xiao MB
J Gastrointest Oncol; 2022 Oct; 13(5):2553-2564. PubMed ID: 36388690
[TBL] [Abstract][Full Text] [Related]
39. A signature based on m6A pattern and tumor microenvironment infiltration in clear cell renal cell carcinoma.
Yang C; Yu T; Li Q; Xie F; Lin Q
Am J Transl Res; 2022; 14(7):4931-4947. PubMed ID: 35958449
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of the m6A-related molecular patterns and diagnostic biomarkers in osteoporosis.
Bai Q; Shi M; Sun X; Lou Q; Peng H; Qu Z; Fan J; Dai L
Front Endocrinol (Lausanne); 2022; 13():957742. PubMed ID: 36034449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
